Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066844 · ClinicalTrials.gov registry record · Phase 2
Navigator vs Standard Needle Injection for Hip
A Phase 2 study of Hip Pain Etiology Unknown, sponsored by Cartiva.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02066844: Completed Phase 2 study of Hip Pain Etiology Unknown, sponsored by Cartiva.
NCT02066844 is a Phase 2 study of Hip Pain Etiology Unknown that has completed, run by Cartiva. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066844, a Phase 2 study of Hip Pain Etiology Unknown, has completed, sponsored by Cartiva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared between a Navigator injection and a standard hip injection. The data collected from this pilot study will serve as the basis to design a larger multi-center study.
Conditions Studied
Interventions
- DRUG Lidocaine
- DRUG Celestone
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT02066844 record still lists
NCT02066844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Hip Pain Etiology Unknown appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine is the first listed.
NCT02066844 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02066844 about?
NCT02066844 is a clinical study titled "Navigator vs Standard Needle Injection for Hip". The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared ...
What is the current status of trial NCT02066844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2014-02. Estimated completion is 2014-08.
What conditions does trial NCT02066844 study?
This clinical trial studies the following conditions: Hip Pain Etiology Unknown.
What interventions are being tested in trial NCT02066844?
The interventions under investigation include: Lidocaine (DRUG), Celestone (DRUG).
Who is sponsoring clinical trial NCT02066844?
This trial is sponsored by Cartiva, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02066844 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02066844's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia